Mavacamten Use for Obstructive Hypertrophic Cardiomyopathy and Effect on Beta-Blocker Therapy in an Academic Institution

Purpose: Mavacamten is the first and only cardiac myosin inhibitor approved for the management of obstructive hypertrophic cardiomyopathy (oHCM). While it has been shown to decrease left ventricular outflow tract (LVOT) obstruction in landmark trials, studies on real-world use of mavacamten are still ongoing. First-line therapy includes β-blocker and calcium channel blockers (CCB), with disopyramide as an option for refractory patients. In the EXPLORER-HCM trial, 76% of patients (n = 94) on mavacamten were also on beta-blocker, with only 17% (n= 16) requiring adjustments to the dose of β-blocker therapy.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Source Type: research